[SCHEDULE 13D/A] CITIUS ONCOLOGY, INC. SEC Filing
Citius Pharmaceuticals, Inc. amended its Schedule 13D to reflect a registered direct offering on September 10, 2025 that issued 5,142,858 new common shares of Citius Oncology, Inc. After that issuance the reporting person, Citius Pharmaceuticals, Inc., beneficially owns 66,049,615 shares, representing approximately 79.1% of the issued and outstanding common stock based on a total of 83,513,442 shares. The filing states the reporting person has sole voting and dispositive power over those shares. The amendment updates prior Schedule 13D filings to give effect to the new issuance.
Citius Pharmaceuticals, Inc. ha modificato il proprio Schedule 13D per riflettere un’offerta diretta registrata il 10 settembre 2025 che ha emesso 5.142.858 nuove azioni ordinarie di Citius Oncology, Inc. Dopo tale emissione, il soggetto segnalante, Citius Pharmaceuticals, Inc., detiene in modo beneficio 66.049.615 azioni, rappresentando circa 79.1% delle azioni ordinarie emesse e in circolazione su un totale di 83.513.442 azioni. La dichiarazione indica che il soggetto segnalante possiede potere di voto e disposizione esclusivo su tali azioni. La modifica aggiorna le precedenti presentazioni Schedule 13D per dare effetto alla nuova emissione.
Citius Pharmaceuticals, Inc. enmendó su Schedule 13D para reflejar una oferta directa registrada el 10 de septiembre de 2025 que emitió 5,142,858 nuevas acciones comunes de Citius Oncology, Inc. Después de dicha emisión, la persona informante, Citius Pharmaceuticals, Inc., posee de forma beneficiosa 66,049,615 acciones, que representan aproximadamente 79.1% del capital social común emitido y en circulación basado en un total de 83,513,442 acciones. El archivo indica que la persona informante tiene poder de voto y disposición exclusivo sobre dichas acciones. La enmienda actualiza presentaciones previas de Schedule 13D para dar efecto a la nueva emisión.
Citius Pharmaceuticals, Inc.는 2025년 9월 10일에 등록된 직접 공모를 반영하기 위해 Schedule 13D를 수정했으며, 이는 Citius Oncology, Inc.의 5,142,858주 신규 보통주를 발행했습니다. 이 발행 이후 보고당사자(Citius Pharmaceuticals, Inc.)는 66,049,615주를 실질적으로 소유하게 되었으며, 이는 총 83,513,442주 중 약 79.1%에 해당합니다. 신고서에는 보고당사자가 해당 주식에 대해 단독 의결권 및 처분권을 보유한다고 명시되어 있습니다. 이 수정은 신규 발행을 반영하기 위해 이전의 Schedule 13D 제출을 업데이트합니다.
Citius Pharmaceuticals, Inc. a modifié son Schedule 13D pour refléter une offre directe enregistrée le 10 septembre 2025 qui a émis 5 142 858 nouvelles actions ordinaires de Citius Oncology, Inc. Après cette émission, la personne déclarant, Citius Pharmaceuticals, Inc., détient de manière bénéficiaire 66 049 615 actions, représentant environ 79.1% des actions ordinaires émises et en circulation sur la base d’un total de 83 513 442 actions. Le dépôt indique que la personne déclarante dispose d’un pouvoir de vote et de disposition exclusif sur ces actions. L’amendement met à jour les dépôts Schedule 13D antérieurs pour donner effet à la nouvelle émission.
Citius Pharmaceuticals, Inc. hat seine Schedule 13D dahingehend geändert, dass ein registriertes Direct Offering am 10. September 2025 ausgegeben wurde, das 5.142.858 neue Stammaktien von Citius Oncology, Inc. ausgab. Nach dieser Emission besitzt die meldende Person, Citius Pharmaceuticals, Inc., beneficially 66.049.615 Aktien, was etwa 79.1% des ausgegebenen und umlaufenden Stammkapitals basierend auf insgesamt 83.513.442 Aktien entspricht. Die Einreichung besagt, dass die meldende Person über einzelne Stimm- und Verfügungsgewalt über diese Aktien verfügt. Die Änderung aktualisiert frühere Schedule-13D-Einreichungen, um die neue Ausgabe zu berücksichtigen.
Citius Pharmaceuticals, Inc. عدّلت Schedule 13D لديها لتعكس عرضاً مباشراً مسجلاً في 10 سبتمبر 2025 صدر عنه 5,142,858 سهماً عاديّاً جديداً لشركة Citius Oncology, Inc. بعد هذه الإصدار، تمتلك جهة الإبلاغ، Citius Pharmaceuticals, Inc., بشكل فعّال 66,049,615 سهماً، تشكّل ما يقرب من 79.1% من الأسهم العادية المصدرة والقابلة للتداول، استناداً إلى إجمالي 83,513,442 سهماً. تذكر الوثيقة أن جهة الإبلاغ لديها سلطة تصويت وتصرّف حصرية على تلك الأسهم. تقوم التعديلات بتحديث التقديمات السابقة لـ Schedule 13D من أجل تنفيذ الإصدار الجديد.
Citius Pharmaceuticals, Inc. 已修订其 Schedule 13D，以反映2025年9月10日的一项注册直接发行，发行了Citius Oncology, Inc.的5,142,858股新普通股。发行后，申报人Citius Pharmaceuticals, Inc.在实益上拥有66,049,615股，约占已发行并在外流通的普通股的79.1%，基于总计83,513,442股。该文件显示申报人对上述股份拥有单独表决权和处置权。本次修订更新了先前的Schedule 13D备案，以使新发行生效。
- Transparent update to Schedule 13D reflecting the September 10, 2025 registered direct offering
- Majority stake disclosed: reporting person beneficially owns 66,049,615 shares (approximately 79.1%)
- Sole voting and dispositive power reported, clarifying control of the shares
- High ownership concentration: 79.1% beneficial ownership reduces public float and concentrates control
- Dilutive event: issuer sold and issued 5,142,858 shares in the registered direct offering
Insights
TL;DR: Majority ownership disclosed after a registered direct offering; material for control and share float.
The Schedule 13D/A confirms that Citius Pharmaceuticals holds a controlling stake of 79.1% in Citius Oncology following the issuance of 5,142,858 new shares on September 10, 2025. From a capital-structure perspective, this reduces the public float and concentrates voting power, which can affect liquidity and potential market trading dynamics. The filing reports sole voting and dispositive power over 66,049,615 shares, aligning ownership and control in one reporting person.
TL;DR: The filing documents clear control by a single entity, a material corporate-governance development for minority holders.
The amendment explicitly states sole voting and dispositive authority over a ~79% ownership stake, established after a registered direct offering. Such concentration is material for governance because it gives the reporting person effective control over corporate decisions, including board composition and strategic direction. The Schedule 13D/A updates prior disclosures to reflect the dilutive issuance and the resulting ownership percentage.
Citius Pharmaceuticals, Inc. ha modificato il proprio Schedule 13D per riflettere un’offerta diretta registrata il 10 settembre 2025 che ha emesso 5.142.858 nuove azioni ordinarie di Citius Oncology, Inc. Dopo tale emissione, il soggetto segnalante, Citius Pharmaceuticals, Inc., detiene in modo beneficio 66.049.615 azioni, rappresentando circa 79.1% delle azioni ordinarie emesse e in circolazione su un totale di 83.513.442 azioni. La dichiarazione indica che il soggetto segnalante possiede potere di voto e disposizione esclusivo su tali azioni. La modifica aggiorna le precedenti presentazioni Schedule 13D per dare effetto alla nuova emissione.
Citius Pharmaceuticals, Inc. enmendó su Schedule 13D para reflejar una oferta directa registrada el 10 de septiembre de 2025 que emitió 5,142,858 nuevas acciones comunes de Citius Oncology, Inc. Después de dicha emisión, la persona informante, Citius Pharmaceuticals, Inc., posee de forma beneficiosa 66,049,615 acciones, que representan aproximadamente 79.1% del capital social común emitido y en circulación basado en un total de 83,513,442 acciones. El archivo indica que la persona informante tiene poder de voto y disposición exclusivo sobre dichas acciones. La enmienda actualiza presentaciones previas de Schedule 13D para dar efecto a la nueva emisión.
Citius Pharmaceuticals, Inc.는 2025년 9월 10일에 등록된 직접 공모를 반영하기 위해 Schedule 13D를 수정했으며, 이는 Citius Oncology, Inc.의 5,142,858주 신규 보통주를 발행했습니다. 이 발행 이후 보고당사자(Citius Pharmaceuticals, Inc.)는 66,049,615주를 실질적으로 소유하게 되었으며, 이는 총 83,513,442주 중 약 79.1%에 해당합니다. 신고서에는 보고당사자가 해당 주식에 대해 단독 의결권 및 처분권을 보유한다고 명시되어 있습니다. 이 수정은 신규 발행을 반영하기 위해 이전의 Schedule 13D 제출을 업데이트합니다.
Citius Pharmaceuticals, Inc. a modifié son Schedule 13D pour refléter une offre directe enregistrée le 10 septembre 2025 qui a émis 5 142 858 nouvelles actions ordinaires de Citius Oncology, Inc. Après cette émission, la personne déclarant, Citius Pharmaceuticals, Inc., détient de manière bénéficiaire 66 049 615 actions, représentant environ 79.1% des actions ordinaires émises et en circulation sur la base d’un total de 83 513 442 actions. Le dépôt indique que la personne déclarante dispose d’un pouvoir de vote et de disposition exclusif sur ces actions. L’amendement met à jour les dépôts Schedule 13D antérieurs pour donner effet à la nouvelle émission.
Citius Pharmaceuticals, Inc. hat seine Schedule 13D dahingehend geändert, dass ein registriertes Direct Offering am 10. September 2025 ausgegeben wurde, das 5.142.858 neue Stammaktien von Citius Oncology, Inc. ausgab. Nach dieser Emission besitzt die meldende Person, Citius Pharmaceuticals, Inc., beneficially 66.049.615 Aktien, was etwa 79.1% des ausgegebenen und umlaufenden Stammkapitals basierend auf insgesamt 83.513.442 Aktien entspricht. Die Einreichung besagt, dass die meldende Person über einzelne Stimm- und Verfügungsgewalt über diese Aktien verfügt. Die Änderung aktualisiert frühere Schedule-13D-Einreichungen, um die neue Ausgabe zu berücksichtigen.
FAQ
How many Citius Oncology (CTOR) shares are outstanding after the issuance?
How many CTOR shares does Citius Pharmaceuticals beneficially own?
When were the additional CTOR shares issued and how many were issued?
Does the reporting person have voting control over the shares?
Who signed the Schedule 13D/A filing for the reporting person?
